JP2012506451A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506451A5 JP2012506451A5 JP2011533341A JP2011533341A JP2012506451A5 JP 2012506451 A5 JP2012506451 A5 JP 2012506451A5 JP 2011533341 A JP2011533341 A JP 2011533341A JP 2011533341 A JP2011533341 A JP 2011533341A JP 2012506451 A5 JP2012506451 A5 JP 2012506451A5
- Authority
- JP
- Japan
- Prior art keywords
- fluid
- cell
- oxygen
- item
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012530 fluid Substances 0.000 claims description 53
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 29
- 239000001301 oxygen Substances 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 27
- 210000000170 Cell Membrane Anatomy 0.000 claims description 24
- 230000000051 modifying Effects 0.000 claims description 23
- 230000001404 mediated Effects 0.000 claims description 20
- 102100005170 CRLF2 Human genes 0.000 claims description 18
- 101700020064 CRLF2 Proteins 0.000 claims description 18
- 201000008937 atopic dermatitis Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 210000004027 cells Anatomy 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 14
- 239000002086 nanomaterial Substances 0.000 claims description 14
- 102100005288 TSLP Human genes 0.000 claims description 12
- 101700027709 TSLP Proteins 0.000 claims description 12
- 230000000172 allergic Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 102000003688 G-protein coupled receptors Human genes 0.000 claims description 8
- 108090000045 G-protein coupled receptors Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 206010003246 Arthritis Diseases 0.000 claims description 6
- 206010021425 Immune system disease Diseases 0.000 claims description 6
- 210000004379 Membranes Anatomy 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- 230000002757 inflammatory Effects 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- BPZSYCZIITTYBL-YJYMSZOUSA-N Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 claims description 5
- 210000000987 Immune System Anatomy 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 229960002848 formoterol Drugs 0.000 claims description 5
- 239000003607 modifier Substances 0.000 claims description 5
- 208000006673 Asthma Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 102000019460 EC 4.6.1.1 Human genes 0.000 claims description 4
- 108060000200 EC 4.6.1.1 Proteins 0.000 claims description 4
- 210000000981 Epithelium Anatomy 0.000 claims description 4
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 4
- 210000000138 Mast Cells Anatomy 0.000 claims description 4
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 4
- 206010039083 Rhinitis Diseases 0.000 claims description 4
- 230000003042 antagnostic Effects 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 239000000812 cholinergic antagonist Substances 0.000 claims description 4
- 230000001419 dependent Effects 0.000 claims description 4
- 235000020932 food allergy Nutrition 0.000 claims description 4
- 150000002617 leukotrienes Chemical class 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000000414 obstructive Effects 0.000 claims description 4
- 201000004681 psoriasis Diseases 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 102000027575 transmembrane receptors Human genes 0.000 claims description 4
- 108091007901 transmembrane receptors Proteins 0.000 claims description 4
- 229940023808 Albuterol Drugs 0.000 claims description 3
- 229960004436 Budesonide Drugs 0.000 claims description 3
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 claims description 3
- 206010016946 Food allergy Diseases 0.000 claims description 3
- 229960001888 Ipratropium Drugs 0.000 claims description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 3
- -1 metiprednisolone Chemical compound 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 229960002052 salbutamol Drugs 0.000 claims description 3
- 229960004017 salmeterol Drugs 0.000 claims description 3
- 230000000699 topical Effects 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 2
- 229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 claims description 2
- 229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 2
- 229960002170 Azathioprine Drugs 0.000 claims description 2
- 210000002390 Cell Membrane Structures Anatomy 0.000 claims description 2
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims description 2
- 229960001334 Corticosteroids Drugs 0.000 claims description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N Cromoglicic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 2
- 229940009997 Cromolyn Drugs 0.000 claims description 2
- 229940119017 Cyclosporine Drugs 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 210000001047 Desmosomes Anatomy 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N Diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
- 108060003339 GPLD1 Proteins 0.000 claims description 2
- 210000003976 Gap Junctions Anatomy 0.000 claims description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N Hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 2
- 108060003951 Immunoglobulins Proteins 0.000 claims description 2
- 102000018358 Immunoglobulins Human genes 0.000 claims description 2
- 210000004347 Intestinal Mucosa Anatomy 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 claims description 2
- 108090000862 Ion Channels Proteins 0.000 claims description 2
- 229940087612 Levalbuterol Drugs 0.000 claims description 2
- NDAUXUAQIAJITI-LBPRGKRZSA-N Levosalbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 2
- 229960003088 Loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N Loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- 210000004072 Lung Anatomy 0.000 claims description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 2
- 108010061543 Neutralizing Antibodies Proteins 0.000 claims description 2
- KASDHRXLYQOAKZ-XDSKOBMDSA-N Pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 claims description 2
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 210000001578 Tight Junctions Anatomy 0.000 claims description 2
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 claims description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004764 Zafirlukast Drugs 0.000 claims description 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 2
- 230000001078 anti-cholinergic Effects 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 230000003197 catalytic Effects 0.000 claims description 2
- 230000024881 catalytic activity Effects 0.000 claims description 2
- 230000021164 cell adhesion Effects 0.000 claims description 2
- 229960001803 cetirizine Drugs 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 229960000265 cromoglicic acid Drugs 0.000 claims description 2
- 229910001882 dioxygen Inorganic materials 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- 229940079593 drugs Drugs 0.000 claims description 2
- 229960002714 fluticasone Drugs 0.000 claims description 2
- 102000037240 fusion proteins Human genes 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960000930 hydroxyzine Drugs 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 230000003834 intracellular Effects 0.000 claims description 2
- 230000031146 intracellular signal transduction Effects 0.000 claims description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N levocetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 2
- 229950008204 levosalbutamol Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000006011 modification reaction Methods 0.000 claims description 2
- 229960005127 montelukast Drugs 0.000 claims description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 229960005330 pimecrolimus Drugs 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 229940110309 tiotropium Drugs 0.000 claims description 2
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims description 2
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims description 2
- 229960005332 zileuton Drugs 0.000 claims description 2
- 102000034438 G alpha subunit Human genes 0.000 claims 3
- 108091006083 G alpha subunit Proteins 0.000 claims 3
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- 230000033228 biological regulation Effects 0.000 claims 2
- 230000001413 cellular Effects 0.000 claims 2
- 238000011105 stabilization Methods 0.000 claims 2
- 229960000278 Theophylline Drugs 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 108091006011 G proteins Proteins 0.000 description 3
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 3
- XVEDWGDCDJUXSW-UHFFFAOYSA-N 1-methylxanthen-9-one Chemical compound O1C2=CC=CC=C2C(=O)C2=C1C=CC=C2C XVEDWGDCDJUXSW-UHFFFAOYSA-N 0.000 description 1
- 229940092705 Beclomethasone Drugs 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N Flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229960001664 Mometasone Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N Nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229960001967 Tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000003182 bronchodilatating Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 230000001299 hyperoxygenation Effects 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10745308P | 2008-10-22 | 2008-10-22 | |
| US10748008P | 2008-10-22 | 2008-10-22 | |
| US61/107,453 | 2008-10-22 | ||
| US61/107,480 | 2008-10-22 | ||
| US12/258,210 | 2008-10-24 | ||
| US12/258,210 US20090274730A1 (en) | 2007-10-25 | 2008-10-24 | Compositions and methods for treating inflammation |
| PCT/US2009/061710 WO2010048425A1 (fr) | 2008-10-22 | 2009-10-22 | Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014246760A Division JP2015044869A (ja) | 2008-10-22 | 2014-12-05 | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506451A JP2012506451A (ja) | 2012-03-15 |
| JP2012506451A5 true JP2012506451A5 (fr) | 2012-12-06 |
| JP5688370B2 JP5688370B2 (ja) | 2015-03-25 |
Family
ID=42119683
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533341A Expired - Fee Related JP5688370B2 (ja) | 2008-10-22 | 2009-10-22 | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法 |
| JP2011533355A Expired - Fee Related JP5688371B2 (ja) | 2008-10-22 | 2009-10-22 | マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法 |
| JP2014246753A Withdrawn JP2015044868A (ja) | 2008-10-22 | 2014-12-05 | マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法 |
| JP2014246760A Withdrawn JP2015044869A (ja) | 2008-10-22 | 2014-12-05 | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533355A Expired - Fee Related JP5688371B2 (ja) | 2008-10-22 | 2009-10-22 | マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法 |
| JP2014246753A Withdrawn JP2015044868A (ja) | 2008-10-22 | 2014-12-05 | マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法 |
| JP2014246760A Withdrawn JP2015044869A (ja) | 2008-10-22 | 2014-12-05 | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP2350263A4 (fr) |
| JP (4) | JP5688370B2 (fr) |
| CN (2) | CN102256607B (fr) |
| AU (2) | AU2009308302B2 (fr) |
| BR (2) | BRPI0920430A2 (fr) |
| CA (2) | CA2741336A1 (fr) |
| IL (2) | IL212277A0 (fr) |
| MX (2) | MX2011004233A (fr) |
| WO (2) | WO2010048455A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
| WO2008052145A2 (fr) | 2006-10-25 | 2008-05-02 | Revalesio Corporation | Procédés de traitement thérapeutique des yeux et d'autres tissus humains à l'aide d'une solution enrichie en oxygène |
| US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
| EP2086668B1 (fr) | 2006-10-25 | 2016-11-16 | Revalesio Corporation | Dispositif de mélange et procédé |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| MX337862B (es) * | 2008-04-28 | 2016-03-16 | Revalesio Corp | Composiciones y métodos para el tratamiento de la esclerosis multiple. |
| CA2723215A1 (fr) | 2008-05-01 | 2009-11-05 | Revalesio Corporation | Compositions et methodes de traitement de troubles digestifs |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| CA2798690A1 (fr) | 2010-05-07 | 2011-11-10 | Revalesio Corporation | Compositions et procedes d'amelioration des performances physiologiques et du temps de recuperation |
| MX2013001636A (es) | 2010-08-12 | 2013-05-01 | Revalesio Corp | Composiciones y metodos para el tratamiento de taupatias |
| EA201391521A1 (ru) * | 2011-04-13 | 2014-03-31 | Ревалезио Корпорейшн | Композиции и способы для ингибирования и/или модулирования эффекторных t-клеток, участвующих в воспалительном нейродегенеративном заболевании |
| CN102250213B (zh) * | 2011-07-01 | 2012-11-07 | 中国药科大学 | 基质金属蛋白酶-9多肽抑制剂3及其应用 |
| CN102268069B (zh) * | 2011-07-01 | 2012-11-28 | 中国药科大学 | 基质金属蛋白酶-9多肽抑制剂4及其应用 |
| CN102268070B (zh) * | 2011-07-01 | 2012-11-28 | 中国药科大学 | 基质金属蛋白酶-9多肽抑制剂2及其应用 |
| KR101492435B1 (ko) * | 2012-12-28 | 2015-02-10 | 고려대학교 산학협력단 | ＨＩＦ１α ｓｉＲＮＡ를 유효성분으로 함유하는 ＴＳＬＰ에 의해 매개되는 질환 예방 또는 치료용 약제학적 조성물 |
| GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| CN105477628B (zh) * | 2014-09-19 | 2021-04-30 | 山东蓝金生物工程有限公司 | 抗癌组合物及其用途 |
| CN106943593A (zh) * | 2017-03-24 | 2017-07-14 | 浙江中医药大学 | 抗tslp抗体在制备防治慢性瘙痒药物中的应用 |
| WO2019005948A1 (fr) * | 2017-06-27 | 2019-01-03 | Translational Sciences, Inc. | Inhibition de la métalloprotéinase matricielle 9 vasculaire pour traiter une lésion ischémique |
| CA3140952A1 (fr) * | 2019-05-17 | 2020-11-26 | The Trustees Of The University Of Pennsylvania | Procedes et compositions pour le traitement de l'obesite et/ou de troubles cutanes |
| CN114887053A (zh) * | 2019-11-29 | 2022-08-12 | 康诺亚生物医药科技（成都）有限公司 | 一种tslp相关病症治疗剂的开发和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69936453T2 (de) * | 1998-07-28 | 2008-03-06 | The Regents Of The University Of California, Oakland | Für einen g-protein gekoppelten rezeptor, der an der empfindungstransduktion beteiligt ist, kodierende nukleinsäuren |
| CA2378880C (fr) * | 1999-07-21 | 2010-02-23 | Omeros Medical Systems, Inc. | Solutions et procedes permettant d'inhiber la douleur, les inflammations et la degradation des cartilages |
| US20040235732A1 (en) * | 2000-11-03 | 2004-11-25 | Qun-Yong Zhou | Method for modulating angiogenesis using prokineticin receptor antagonists |
| US20030232114A1 (en) * | 2002-06-13 | 2003-12-18 | Nikola Dekleva | Method for liquid enrichment with oxygen and applications of enriched liquids |
| AU2002321678A1 (en) * | 2002-09-09 | 2004-03-29 | Boros Béla | Oxygen-enriched water, treated within a magnetic field and heavy water |
| US20070077553A1 (en) * | 2003-10-30 | 2007-04-05 | Rosetta Genomics | Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof |
| EP1599165A4 (fr) * | 2003-02-10 | 2010-09-08 | Univ Jefferson | Utilisation de ligands gcc |
| US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US7393924B2 (en) * | 2004-01-06 | 2008-07-01 | Franco Vitaliano | Smart bio-nanoparticle elements |
| KR100583430B1 (ko) * | 2004-03-08 | 2006-05-24 | 양경숙 | 차륜 가변형 스쿠터 |
| US20050249712A1 (en) * | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
| WO2008018932A2 (fr) * | 2006-05-01 | 2008-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Procédé et utilisation de dispositifs à échelle nanométrique pour la réduction d'une lésion tissulaire lors d'un incident ischémique ou de reperfusion |
| WO2008005705A2 (fr) * | 2006-06-30 | 2008-01-10 | Nucryst Pharmaceuticals Corp. | Formulations à teneur métallique et procédés d'utilisation |
| WO2008052145A2 (fr) * | 2006-10-25 | 2008-05-02 | Revalesio Corporation | Procédés de traitement thérapeutique des yeux et d'autres tissus humains à l'aide d'une solution enrichie en oxygène |
| EP2086668B1 (fr) * | 2006-10-25 | 2016-11-16 | Revalesio Corporation | Dispositif de mélange et procédé |
| EP2083876A4 (fr) * | 2006-10-25 | 2012-09-19 | Revalesio Corp | Méthodes de soins et de traitement de plaies |
| WO2009055614A1 (fr) * | 2007-10-25 | 2009-04-30 | Revalesio Corporation | Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire |
| MX337862B (es) * | 2008-04-28 | 2016-03-16 | Revalesio Corp | Composiciones y métodos para el tratamiento de la esclerosis multiple. |
-
2009
- 2009-10-22 CN CN200980151711.6A patent/CN102256607B/zh not_active Expired - Fee Related
- 2009-10-22 JP JP2011533341A patent/JP5688370B2/ja not_active Expired - Fee Related
- 2009-10-22 CN CN200980151710.1A patent/CN102257130B/zh not_active Expired - Fee Related
- 2009-10-22 BR BRPI0920430A patent/BRPI0920430A2/pt not_active IP Right Cessation
- 2009-10-22 WO PCT/US2009/061744 patent/WO2010048455A1/fr active Application Filing
- 2009-10-22 MX MX2011004233A patent/MX2011004233A/es active IP Right Grant
- 2009-10-22 AU AU2009308302A patent/AU2009308302B2/en not_active Ceased
- 2009-10-22 EP EP09822721.8A patent/EP2350263A4/fr not_active Withdrawn
- 2009-10-22 WO PCT/US2009/061710 patent/WO2010048425A1/fr active Application Filing
- 2009-10-22 JP JP2011533355A patent/JP5688371B2/ja not_active Expired - Fee Related
- 2009-10-22 CA CA2741336A patent/CA2741336A1/fr not_active Abandoned
- 2009-10-22 MX MX2011004235A patent/MX337035B/es active IP Right Grant
- 2009-10-22 CA CA2741341A patent/CA2741341A1/fr active Pending
- 2009-10-22 EP EP09822743.2A patent/EP2364154A4/fr not_active Withdrawn
- 2009-10-22 BR BRPI0920201A patent/BRPI0920201A2/pt not_active IP Right Cessation
- 2009-10-22 AU AU2009308362A patent/AU2009308362B2/en not_active Ceased
-
2011
- 2011-04-12 IL IL212277A patent/IL212277A0/en unknown
- 2011-04-13 IL IL212309A patent/IL212309A/en not_active IP Right Cessation
-
2014
- 2014-12-05 JP JP2014246753A patent/JP2015044868A/ja not_active Withdrawn
- 2014-12-05 JP JP2014246760A patent/JP2015044869A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506451A5 (fr) | ||
| JP2011500854A5 (fr) | ||
| JP2011523627A5 (fr) | ||
| JP2012525396A5 (fr) | ||
| Silverman et al. | Involvement of neural transient receptor potential channels in peripheral inflammation | |
| Daley‐Yates | Inhaled corticosteroids: potency, dose equivalence and therapeutic index | |
| HRP20200298T1 (hr) | Pripravci za respiratorno davanje aktivnih sredstava i pripadajući postupci i sustavi | |
| Raissy et al. | Inhaled corticosteroids in lung diseases | |
| JP5688370B2 (ja) | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法 | |
| CA2798127A1 (fr) | Methodes et compositions de protection contre des agents neurotoxiques | |
| Respaud et al. | Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin | |
| HRP20201711T1 (hr) | Postupci liječenja autoimunih, respiratornih i upalnih poremećaja inhalacijom roflumilast n-oksida | |
| EA200801520A1 (ru) | Химерные и гуманизированные антитела против человеческого интерлейкина-13 (il-13) | |
| CN107998109A (zh) | 药物组合物 | |
| Donnelly et al. | Clinical pharmacokinetics of inhaled budesonide | |
| Baptist et al. | Inhaled corticosteroids for asthma: are they all the same? | |
| EP3570848A1 (fr) | Compositions pharmaceutiques nasales pour réduire les risques d'exposition à des polluants atmosphériques | |
| JP2019503997A5 (fr) | ||
| Pazos-Castro et al. | Suitability of potyviral recombinant virus-like particles bearing a complete food allergen for immunotherapy vaccines | |
| KR101475262B1 (ko) | 천식 치료에 사용되는 흡입용 복합 조성물 | |
| US20130156823A1 (en) | Excipient-free Aerosol Formulation | |
| RU2006113701A (ru) | Лечение респираторных заболеваний антителами против рецептора il-2 | |
| Carlsen et al. | Pharmaceutical treatment strategies for childhood asthma | |
| US10954307B2 (en) | Targeted delivery methods and compositions for antihistamines | |
| Nazarova et al. | Relvar Ellipta®-new molecule in a new delivery system-new horizons in the treatment of bronchial asthma |